Divalproex Sodium Tablet, Delayed Release
Product Images NDC 17856-0797

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 17856-0797). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex 250 mg Label (17856 0797 01 Label)

Divalproex  250 mg Label (17856 0797 01 Label)
This is a description of a medication called Divalproex Sodium, which is contained in a delayed-release tablet with a strength of 250 mg per tablet. The medication is only available with a prescription and should be kept out of the reach of children. The tablet comes in a unit dose packaging with one tablet per pouch and 100 tablets per case. The package insert should be consulted for indications and dosage schedules, and the medication should be stored at a temperature between 20-25°C (68-77°F). The manufacturer is identified as Migby: i Pharmaceuncar Tnduries and the distributor as Atlantic Boloicals Corp. The label contains lot numbers and an expiration date, and any questions should be directed to the manufacturer's phone number provided.*
FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)
This appears to be a figure showing the results of a study or experiment. It includes various percentages ranging from -100% to 100%, and mentions a "Reduction in CPS Rate". Without further context, it is not possible to provide a more detailed or specific description of the content.*
FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)
The text describes a figure labeled "Figure 4" that shows "Mean 4-week Migraine Rates" for two treatments, "Placebo" and "DVPX" in two different studies labeled "Study 1" and "Study 2". The specific results of the rates are not provided.*
FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.